Whether these modifications which include phosphorylation and ubiquitination (reviewed by [16, 17]) could be harnessed directly or through targeting of BCL3 upstream modifiers, as suggested for the cancer related deubiquitination enzyme CYLD [148], remains to be determined. This evidence concerns the gene CYLD and cancer.